-
Comparative study of different functionalized graphene-nanoplatelet aqueous nanofluids for solar energy applications
Authors:
Javier P. Vallejo,
Luca Mercatelli,
Maria Raffaella Martina,
Daniele Di Rosa,
Aldo Dell'Oro,
Luis Lugo,
Elisa Sani
Abstract:
The optical properties of nanofluids are peculiar and interesting for a variety of applications. Among them, the high light extinction coefficient of nanofluids can be useful in linear parabolic concentrating solar systems, while their properties under high light irradiation intensities can be exploited for direct solar steam generation. The optical characterization of colloids, including the stud…
▽ More
The optical properties of nanofluids are peculiar and interesting for a variety of applications. Among them, the high light extinction coefficient of nanofluids can be useful in linear parabolic concentrating solar systems, while their properties under high light irradiation intensities can be exploited for direct solar steam generation. The optical characterization of colloids, including the study of non-linear optical properties, is thus a needed step to design the use of such novel materials for solar energy exploitation. In this work, we analysed two different types of nanofluids, consisting of polycarboxylate chemically modified graphene nanoplatelets (P-GnP) and sulfonic acid-functionalized graphene nanoplatelets (S-GnP) dispersed in water, at three concentrations from 0.005 wt% to 0.05 wt%. Moderately stable nanofluids were achieved with favourable light extinction properties, as well as a non-linear optical behaviour under high input solar intensities.
△ Less
Submitted 28 April, 2022;
originally announced June 2022.
-
Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: Bayesian evidence synthesis with target trial emulation
Authors:
Sylwia Bujkiewicz,
Janharpreet Singh,
Lorna Wheaton,
David Jenkins,
Reynaldo Martina,
Kimme Hyrich,
Keith R. Abrams
Abstract:
Objective: We aim to utilise real world data in evidence synthesis to optimise an evidence base for the effectiveness of biologic therapies in rheumatoid arthritis in order to allow for evidence on first-line therapies to inform second-line effectiveness estimates. Study design and setting: We use data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)…
▽ More
Objective: We aim to utilise real world data in evidence synthesis to optimise an evidence base for the effectiveness of biologic therapies in rheumatoid arthritis in order to allow for evidence on first-line therapies to inform second-line effectiveness estimates. Study design and setting: We use data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) to supplement RCT evidence obtained from the literature, by emulating target trials of treatment sequences to estimate treatment effects in each line of therapy. Treatment effects estimates from the target trials inform a bivariate network meta-analysis (NMA) of first and second-line treatments. Results: Summary data were obtained from 21 trials of biologic therapies including 2 for second-line treatment and results from six emulated target trials of both treatment lines. Bivariate NMA resulted in a decrease in uncertainty around the effectiveness estimates of the second-line therapies, when compared to the results of univariate NMA, and allowed for predictions of treatment effects not evaluated in second-line RCTs. Conclusion: Bivariate NMA provides effectiveness estimates for all treatments in first- and second-line, including predicted effects in second-line where these estimates did not exist in the data. This novel methodology may have further applications, for example for bridging networks of trials in children and adults.
△ Less
Submitted 5 January, 2022;
originally announced January 2022.
-
The use of registry data to extrapolate overall survival results from randomised controlled trials
Authors:
Reynaldo Martina,
Keith Abrams,
Sylwia Bujkiewicz,
David Jenkins,
Pascale Dequen,
Michael Lees,
Frank A. Corvino,
Jessica Davies
Abstract:
Background: Pre-marketing authorisation estimates of survival are generally restricted to those observed directly in randomised controlled trials (RCTs). However, for regulatory and Health Technology Assessment (HTA) decision-making a longer time horizon is often required than is studied in RCTs. Therefore, extrapolation is required to estimate long-term treatment effect. Registry data can provide…
▽ More
Background: Pre-marketing authorisation estimates of survival are generally restricted to those observed directly in randomised controlled trials (RCTs). However, for regulatory and Health Technology Assessment (HTA) decision-making a longer time horizon is often required than is studied in RCTs. Therefore, extrapolation is required to estimate long-term treatment effect. Registry data can provide evidence to support extrapolation of treatment effects from RCTs, which are considered the main sources of evidence of effect for new drug applications. A number of methods are available to extrapolate survival data, such as Exponential, Weibull, Gompertz, log-logistic or log-normal parametric models. The different methods have varying functional forms and can result in different survival estimates.
Methods: The aim of this paper was to use registry data to supplement the relatively short term RCT data to obtain long term estimates of effect. No formal hypotheses were tested. We explore the above parametric regression models as well as a nonparametric regression model based on local linear (parametric) regression. We also explore a Bayesian model constrained to the long term estimate of survival reported in literature, a Bayesian power prior approach on the variability observed from published literature, and a Bayesian Model Averaging (BMA) approach. The methods were applied to extrapolate overall survival of a RCT in metastatic melanoma.
Results: The results showed that the BMA approach was able to fit the RCT data well, with the lowest variability of the area under the curve up to 72 months with or without the SEER Medicare registry.
Conclusion: the BMA approach is a viable approach to extrapolate overall survival in the absence of long term data.
△ Less
Submitted 24 October, 2019;
originally announced November 2019.
-
Methods for the inclusion of real world evidence in network meta-analysis
Authors:
David Jenkins,
Humaira Hussein,
Reynaldo Martina,
Pascale Dequen-O'Byrne,
Keith R Abrams,
Sylwia Bujkiewicz
Abstract:
Background: Network Meta-Analysis (NMA) is a key component of submissions to reimbursement agencies world-wide, especially when there is limited direct head-to-head evidence for multiple technologies from randomised controlled trials (RCTs). Many NMAs include only data from RCTs. However, real-world evidence (RWE) is also becoming widely recognised as a valuable source of clinical data. We investi…
▽ More
Background: Network Meta-Analysis (NMA) is a key component of submissions to reimbursement agencies world-wide, especially when there is limited direct head-to-head evidence for multiple technologies from randomised controlled trials (RCTs). Many NMAs include only data from RCTs. However, real-world evidence (RWE) is also becoming widely recognised as a valuable source of clinical data. We investigate methods for the inclusion of RWE in NMA and its impact on the uncertainty around the effectiveness estimates.
Methods: A range of methods for inclusion of RWE in evidence synthesis, including Bayesian hierarchical and power prior models, were investigated by applying them to an example in relapsing remitting multiple sclerosis. The effect of the inclusion of RWE was investigated by varying the degree of down weighting of this part of evidence by the use of a power prior.
Results: Whilst the inclusion of the RWE led to an increase in the level of uncertainty surrounding effect estimates in this example, this depended on the method of inclusion adopted for the RWE. Power prior NMA model resulted in stable effect estimates for fingolimod yet increasing the width of the credible intervals with increasing weight given to RWE data. The hierarchical NMA models were effective in allowing for heterogeneity between study designs; however, this also increased the level of uncertainty.
Conclusion: The power prior approach for the inclusion of RWE in NMAs indicates that the degree to which RWE is taken into account can have a significant impact on the overall level of uncertainty. The hierarchical modelling approach further allowed for accommodating differences between study types. Consequently, further work investigating both empirical evidence for biases associated with individual RWE studies and methods of elicitation from experts on the extent of such biases is warranted.
△ Less
Submitted 22 July, 2021; v1 submitted 17 May, 2018;
originally announced May 2018.
